A survey of new Rx, new generic, and new OTC products
RX CARE
New drugs
Forest Laboratories' Teflaro (ceftaroline fosamil), a broad-spectrum bactericidal cephalosporin with activity against both gram-positive and gram-negative microorganisms, was approved by FDA for treatment of community-acquired bacterial pneumonia (CABP), including cases caused by Streptococcus pneumoniae bacteremia, and acute bacterial skin and skin structure infection (ABSSSI), including cases caused by methicillin-resistant Staphylococcus aureus (MRSA). ( http://www.FRX.com/)
FDA approved Axiron (testosterone topical solution), from Eli Lilly and Acrux Pharma for replacement therapy in men aged ≥18 years for conditions associated with a deficiency or absence of endogenous testosterone. ( http://www.lilly.com/ / 800-545-5979)
FDA approved Avanir Pharmaceuticals' Nuedexta (dextromethorphan hydrobromide and quinidine sulfate) capsules as the first treatment for pseudobulbar affect (PBA). ( http://www.avanir.com/)
OCuSoft's Zytaze (zinc citrate and phytase) has been approved as a medical food providing nutritional support to enhance the effectiveness of botulinum toxin injections in the treatment of blepharospasm, hemifacial spasm, or facial cosmetic procedures. ( http://www.zytaze.com/ / 800-233-5469)
FDA Approves Aprocitentan For Treatment of Uncontrolled High Blood Pressure
March 20th 2024Aprocitentan (TRYVIO) from pharmaceutical company Idorsia demonstrated statistically significant and clinically meaningful reductions in blood pressure in combination with other antihypertensive therapies.